September 30, 2024

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Completion of US FDA Inspection at Unit II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana from September 23 to 27, 2024.

The inspection closed with 10 observations. The observations are of procedural in nature and will be responded to within the stipulated time.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

The US FDA audit concluded on Friday, September 27, 2024 at 8.00 PM. Because of non-availability of senior technical team to review the nature of observations, there is a delay in intimation.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by BADDIGAM ADI REDDY
Date: 2024.09.30 13:18:13 +05'30'

B. Adi Reddy
Company Secretary